Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT01895842 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: Ruxolitinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]